CSF3 and acute myeloid leukemia: Among our 95 IR-AML patients, excluding 10 patients who did not receive any chemotherapy or were only treated with low-dose cytosine arabinoside because of old age and/or poor performance status, sixty-five patients received conventional induction chemotherapy with one of the anthracyclines (idarubicin or doxorubicin) or mitoxantrone for 3 days and cytarabine for 7 days, another twenty patients received DCAG (decitabine 10 mg/m2 d1-5, aclarubicin 20mg d1,3,5, cytarabine 10mg/m2 q12h d1-5, G-CSF 300μg/day) regimen.